Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2781-2787

  Nieto, J ^a   Alvar, J ^a   Mullen, A B ^c   Carter, K C ^c   Rodriguez C ^c   San Andres M I ^b   San Andres M D ^b   Baillie, A J ^c,d   Gonzalez F ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d ProPharma Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; DEXTRAN; NONIONIC SURFACTANT; STIBOGLUCONATE SODIUM; TETRAETHYLENE GLYCOL N HEXADECYL ETHER; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; CHILL; CONTROLLED STUDY; DIARRHEA; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; ENCAPSULATION; FEMALE; LIVER DYSFUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; ASPARTATE AMINOTRANSFERASES; CHEMISTRY, PHARMACEUTICAL; DEXTRANS; DOGS; EXCIPIENTS; FEMALE; INJECTIONS, INTRAVENOUS; IRON; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MICE; MICE, INBRED BALB C; SURFACE-ACTIVE AGENTS; SUSPENSIONS;

EID: 0042424608     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2781-2787.2003     Document Type: Article

References (39)

1. Al Khawajah, A., E. B. Larbi, S. Jain, Y. Al-Gindan, and A. Abahussain. 1992. Subacute toxicity of pentavalent antimony compounds in rats. Hum. Exp. Toxicol. 11:283-288.
2. Alvar, J., R. Molina, M. San Andrés, M. Tesouro, J. Nieto, M. Vitutia, F. González, M. D. San Andrés, J. Boggio, F. Rodríguez, A. Sainz, and C. Escacena. 1994. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88:371-378.
3. Banduwardene, R., A. B. Mullen, and K. C. Carter. 1997. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium Stibogluconate formulations. Int. J. Immunopharmacol. 19:195-203.
4. Belloli, C., L. Ceci, S. Carli, P. Tassi, C. Montesissa, G. De Natale, G. Marcotrigiano, and P. Ormas. 1995. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis. Res. Vet. Sci. 58:123-127.
5. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
6. Bradley, D. J., and J. Kirkley. 1977. Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol. 30:119-129.
7. Carter, K. C., A. J. Baillie, J. Alexander, and T. F. Dolan. 1988. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ dependent. J. Pharm. Pharmacol. 40:370-373.
8. Carter, K. C., A. B. Mullen, S. Sundar, and R. T. Kenney. 2001. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 45:3555-3559.
9. Chapman, W. L., W. L. Hanson, C. R. Alving, and L. D. Hendricks. 1984. Antileishmanial activity of liposome-encapsulated meglumine antimoniate in the dog. Am. J. Vet. Res. 45:1028-1032.
10. Chulay, J. D., L. Fleckenstein, and D. H. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:69-72.
11. Cirugeda, M. E., M. D. Santos, and C. Cirugeda. 1989. Determinación de aluminio en suero por espectrofotometría de absorción atómica con cámara de grafito, p. 12-14. In Proceedings of VII Jornadas Toxicológicas Españolas. Ministerio de Sanidad y Consumo, Madrid, Spain.
12. Collins, M., J. Baillie, and K. C. Carter. 1992. Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection. II. Changes in tissue drug distribution. Int. J. Pharm. 83:251-256.
13. Collins, M., K. C. Carter, A. J. Baillie, and J. O'Grady. 1993. The distribution of free and non-ionic vesicular sodium stibogluconate in dogs. J. Drug Target 1:133-142.
14. Costantini, S., R. Giordano, M. Rizzica, and F. Benedetti. 1985. Applicability of anodic-stripping voltammetry and graphite furnace atomic-absorption spectrometry to the determination of antimony in biological matrices: a comparative study. Analyst 10:1355-1359.
15. Devine, D. V., K. Wong, K. Serrano, A. Chonn, and P. R. Cullis. 1994. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochem. Biophys. Acta 1191:43-51.
16. Godwin, L. G., and J. E. Page. 1943. A study of the excretion of organic antimonials using a polarographic procedure. Biochem. J. 3:198-209.
17. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):133-144.
18. Janknegt, R., S. De Marie, I. A. Bakker-Woudenberg, and D. J. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:279-291.
19. Kaneko, J., J. Harvey, and M. Bruss. 1997. Blood analyte reference values in small and some laboratory animals, p. 895-901. In J. Kaneko, J. Harvey, and M. Bruss (ed.), Clinical biochemistry in domestic animals, 5th ed. Academic Press, Inc., San Diego, Calif.
20. Lira, R., S. Sundar, A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
21. Mancianti, F., M. Gramiccia, L. Gradoni, and S. Pieri. 1988. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans. R. Soc. Trop. Med. Hyg. 82:566-567.
22. Mehvar, R. 2000. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 69:1-25.
23. Mullen, A. B., A. J. Baillie, and K. C. Carter. 1998. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42:2722-2725.
24. O'Connor, W. J., and R. A. Summerill. 1976. The effect of a meal of meat on glomerular filtration rate in dogs at normal urine flows. J. Physiol. 256:81-91.
25. Pamplin, C. L., R. Desjardins, J. Chulay, E. Tramont, L. Hendricks, and C. Canfield. 1981. Pharmacokinetics of antimony during sodium stibogluconate therapy for cutaneous leishmaniasis. Clin. Pharmacol. Ther. 29:270-271.
26. Powers, J. 1990. Statistical analysis of pharmacokinetic data. J. Vet. Pharmacol. Ther. 13:113-120.
27. Rees, P. H., M. I. Keating, P. A. Kager, and W. T. Hockmeyer. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet ii:226-229.
28. Szebeni, J. 1998. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15:57-88.
29. Szebeni, J., and C. R. Alving. 1999. Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif. Cells Blood Substit. Immobil. Biotechnol. 27:23-41.
30. Szebeni, J., J. L. Fontana, N. M. Wassef, P. D. Mongan, D. S. Morse, D. E. Dobbins, G. L. Stahl, R. Bunger, and C. R. Alving. 1999. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99:2302-2309.
31. Tassi, P., M. Madonna, S. Carli, C. Belloli, G. De Natale, L. Ceci, and G. O. Marcotrigiano. 1994. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in dog. Res. Vet. Sci. 56:114-150.
32. Tizard, I. R. 1996. Hypersensitivity type I, p. 369-384. In W. R. Sanders (ed.), Veterinary immunology: an introduction, 5th ed. W. B. Saunders, Philadelphia, Pa.
33. Valladares, J. E., J. Alberola, M. Esteban, and M. Arboix. 1996. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs. Vet. Rec. 138:181-183.
34. Valladares, J. E., J. Freixas, J. Alberola, C. Franquelo, C. Cristofol, and M. Arboix. 1997. Pharmacokinetics of liposome-encapsulated meglumine antimoniate after intramuscular and subcutaneous administration in dogs. Am. J. Trop. Med. Hyg. 57:403-406.
35. Valladares, J. E., C. Riera, J. Alberola, M. Gállego, M. Portús, C. Cristòfol, C. Franquelo, and M. Arboix. 1998. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet. Parasitol. 75:33-40.
36. Valladares, J. E., C. Riera, P. González-Ensenyat, A. Diaz-Cascon, G. Ramos, L. Solano-Gallego, M. Gállego, M. Portús, M. Arboix, and J. Alberola. 2001. Long term improvement in the treatment of canine leishmaniasis using an antimony liposomal formulation. Vet. Parasitol. 97:15-20.
37. Williams, D. M., K. C. Carter, and A. J. Baillie. 1995. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicles preparations of sodium stibogluconate. J. Drug Target 3:1-7.
38. Winship, K. A. 1987. Toxicity of antimony and its compounds. Adverse Drug React. Acute Poisoning Rev. 6:67-90.
39. World Health Organization. 1997. Control of the leishmaniases. Report of a WHO Expert Committee. WHO Technical Report Series. World Health Organization, Geneva, Switzerland.